5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

Autor: O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR, O'Brien, Susan, Moore, Joseph O, Boyd, Thomas E, Larratt, Loree M, Skotnicki, Aleksander B, Koziner, Benjamin, Chanan-Khan, Asher A, Seymour, John F, Gribben, John

Publikováno v: Journal of Clinical Oncology; 11/1/2009, Vol. 27 Issue 31, p5208-5212, 5p

A practical approach to hiring your next business consultant.

Autor: Boyd TE

Publikováno v: Home Healthcare Nurse; 2008 May, Vol. 26 Issue 5, p273-275, 3p

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Autor: Awan, Farrukh T, Hillmen, Peter, Hellmann, Andrzej, Robak, Tadeusz, Hughes, Steven G., Trone, Denise, Shannon, Megan, Flinn, Ian W., Byrd, John C., Riveros, Dardo, Pavlovsky, Santiago, Iastrebner, Claudio M., Carney, Dennis A., Deveridge, Sandra, Durrant, Simon, Hahn, Uwe H., Hertzberg, Mark, Leahy, Michael F., David, Ma, Marlton, Paula, Mulligan, Stephen, Opat, Stephen S., Tiley, Campbell, Wickham, Nicholas W., Cannell, Paul, Gatalano, John, Catalano, John, Cull, Gavin, Luen B., To, Hopfinger, Georg, Jager, Ulrich, Linkesch, Werner, Petzer, Andreas, Schwarzmeier, Josef, Steurer, Michael, Greil, Richard, Bememan, Zwi, Bosly, Andre, Bron, Dominique, Janssens, Ann, Offner, Fritz, Van Den Neste, Eric W., Ka Lung, Wu, Van Hoof, Achiel, Maiolino, Angelo, Pinczowski, Helio, Zanichelli, Maria A., Pereira, Juliana, Larratt, Loree, Spaner, David, Howson Jan, Kang, Chen, Christine I., Cantin, Guy, Fernandez, Louis A., Fraser, Graeme, Mayer, Jiri, Trneny, Marek, Jebavy, Ladislav, Bordessoule, Dominique, Lamy, Thierry, Milpied, Noel, Truchan Graczyk, Malgorzata, Eghbali, Houchingue, Karsenti, Jean Michel, Celigny, Philippe Solal, Mans, Le, Cazin, Bruno, Gyan, Emmanuel, Lepretre, Stephane, Bergmann, Lothar, Tsionos, Konstantinos, Lokeshwar, Nilesh M., Agarwal, Mohan B., Ross, Cecil R., Deshmukh, Chetan D., Narayanan, Geetha, Raina, Vinod, Bondarde, Shailesh A., Shah, Bhavin A., Bairey, Osnat, Tikva, Petach, Shvidel, Lev, Ambrosetti, Achille, Rossi, Policlinico G. B., Angelucci, Emanuele, Carella, Angelo M., Massaia, Massimo, Zinzani, Pier L., Caligaris Cappio, Federico, Foa, Roberto, Gaidano, Gianluca, della Caritá, A. O. Maggiore, Leone, Giuseppe, Santoro, Armando, Griskevicius, Laimonas, Jurgutis, Romualdas, Baker, Bartrum W., Hawkins, Timothy, Corbett, Gillian M., Ganly, Peter, D'Souza, Alvyn B., Deptala, Andrzej, Holowiecki, Jerzy, Kloczko, Janusz, Skotnicki, Aleksander, Zdziarska, Barbara, Kyrcz Krzemien, Slawomira, Dmoszynska, Anna, Moreira, Anna, Pereira, Ana P., Colita, Andrei, Moicean, Andreea D., Vasilica, Mariana, Danaila, Catalin, Gheorghita, Emanuil, Pavlov, Vyacheslav V., Rossiev, Viktor A., Konstantinova, Tatiana, Samoilova, Olga S., Novgorod, Nizhniy, Shelekhova, Tatyana, Zaritsky, Andrey Y., Abdulkadyrov, Kudrat M., Zyuzgin, Ilya S., Pristupa, Alexander S., Loscertales, Javier, Vidal, Joan Besalduch, de Mallorca, Palma, Gonzalez, Marcos, Ortuno, Francisco, Giraldo, Pilar, Nathwani, Amit, Agrawal, Samir G., Rule, Simon, Dearden, Claire E., Bloor, Adrian J., Haynes, Andrew, Singer, Charles, Boclek, Robert G., Bosserman, Linda D., Chan, David, Davidson, Sheldon J., Dichmann, Robert A., Farber, Charles, Hart, Lowell, Hermann, Robert, Eddie, Hu, Janakiraman, Nalini, Jonas, William, Liem, Kiem D., Mcintyre, Rosemary E., O'Brien, Susan, Patel, Giribala, Rado, Thomas, Schilder, Russell, Smith, Scott E., Stock, Wendy, Turturro, Francesco, Venugopal, Parameswaran, Anderson, Thomas C., Berry, William, Boyd, Thomas E., Byrd, John, Cooper, Maureen, Flinn, Ian, Gersh, Robert, Gordon, David, Guzley, Gregory J., Wilks, Sharon T., Klein, Andreas, Krauss, John C., Lister, John, Mandell, Lance, Molina, Arthur, Cooper, Barry, Pendergrass, Kelly B., Reeder, Craig, Savin, Michael A., Spitzer, Gary, Tuscano, Joseph M., Vandeventer, Hendrik, Eradat, Herbert A., Masood, Aisha, Mena, Raul

Publikováno v: British Journal of Haematology, 167, 4, pp. 466-77
British Journal of Haematology, 167, 466-77

Item does not contain fulltext Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533b23d859ca5810398140c50a192122
http://hdl.handle.net/2318/1577053

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Autor: Murray Stewart T; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB 1, Room 562, Baltimore, MD, 21287, USA. tmurray2@jhmi.edu., Von Hoff D; US Oncology Research, The Woodlands, TX, USA.; Translational Genomics Research Institute, Phoenix, AZ, USA., Fitzgerald M; Apex, NC, USA., Marton LJ; Cancer Commons, Mountain View, CA, USA., Becerra CHR; US Oncology Research, The Woodlands, TX, USA.; Texas Oncology, Dallas, TX, USA., Boyd TE; Yakima Valley Memorial Hospital North Star Lodge, Yakima, WA, USA., Conkling PR; US Oncology Research, The Woodlands, TX, USA.; Virginia Oncology Associates, Norfolk, VA, USA., Garbo LE; US Oncology Research, The Woodlands, TX, USA.; New York Oncology Hematology, Albany, NY, USA., Jotte RM; US Oncology Research, The Woodlands, TX, USA.; Rocky Mountain Cancer Centers, Lone Tree, CO, USA., Richards DA; US Oncology Research, The Woodlands, TX, USA.; Texas Oncology, Tyler, TX, USA., Smith DA; Compass Oncology, Vancouver, WA, USA., Stephenson JJ Jr; Prisma Health Cancer Institute (ITOR), Greenville, SC, USA., Vogelzang NJ; US Oncology Research, The Woodlands, TX, USA.; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA., Wu HH; Indiana University Health, Fishers, IN, USA., Casero RA Jr; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB 1, Room 562, Baltimore, MD, 21287, USA. rcasero@jhmi.edu.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB 1, Room 551, Baltimore, MD, 21287, USA. rcasero@jhmi.edu.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Jan; Vol. 87 (1), pp. 135-144. Date of Electronic Publication: 2020 Nov 19.

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.

Autor: Coutre SE; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA., de Vos S; University of California Los Angeles, Los Angeles, CA, USA., Barrientos JC; Hofstra Northwell School of Medicine, Hempstead, NY, USA., Schreeder MT; Clearview Cancer Institute, Huntsville, AL, USA., Wagner-Johnson ND; Washington University, St. Louis, MO, USA., Sharman JP; US Oncology Research and Willamette Valley Cancer Institute and Research Center, Springfield, OR, USA., Boyd TE; US Oncology Research and Willamette Valley Cancer Institute and Research Center, Springfield, OR, USA., Fowler N; University of Texas, MD Anderson Cancer and Research Center, Houston, TX, USA., Dreiling L; Gilead Sciences, Inc, Foster City, CA, USA., Kim Y; Gilead Sciences, Inc, Foster City, CA, USA., Mitra S; Gilead Sciences, Inc, Foster City, CA, USA., Rai K; Hofstra Northwell School of Medicine, Hempstead, NY, USA., Leonard JP; Weill Cornell Medical College, New York, NY, USA., Furman RR; Weill Cornell Medical College, New York, NY, USA.

Publikováno v: HemaSphere [Hemasphere] 2018 Apr 25; Vol. 2 (3), pp. e39. Date of Electronic Publication: 2018 Apr 25 (Print Publication: 2018).